Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 12 5 versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 12 5 versus EVEKEO ODT.
ADDERALL 12.5 vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is pH-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant